Literature DB >> 31468156

Evidence-based MR imaging follow-up strategy for desmoid-type fibromatosis.

P A Gondim Teixeira1, H Biouichi2, W Abou Arab2, M Rios3, F Sirveaux4, G Hossu5, A Blum2.   

Abstract

OBJECTIVES: To propose a follow-up strategy for desmoid-type fibromatosis (DF) based on tumor growth behavior and the signal on T2-weighted MRI.
METHODS: We retrospectively reviewed 296 MRI studies of 34 patients with histologically proven DF. In each study, tumor volume and T2 signal relatively normal striated muscle were assessed. Volume variation and monthly growth rates were analyzed to determine lesion growth behavior (progressing versus stable/regressing lesions). Growth behavior was correlated with T2 signal, tumor location, β-catenin status, treatment strategy, and follow-up duration. Interobserver variability of volume measurements and interobserver measurement variation ratio were assessed.
RESULTS: There were 25 women and 9 men with a mean age of 39.9 ± 19 (4-73) years. Mean follow-up time in the patients included was 55 ± 41 (12-148) months. In progressing lesions, the mean average monthly growth ratio was 10.9 ± 9.2 (1.1-42.5) %. Interobserver variability of volume measurements was excellent (ICC = 0.96). Mean interobserver measurement variation ratio was 20.4 ± 23.6%. The only factor correlated with tumor growth behavior was T2 signal ratio (p < 0.0001). Seventeen out of 34 (50%) patients presented a signal change over the threshold of 1 during follow-up. There were five occurrences of secondary growth after a period of stability with a mean delay until growth of 38.2 ± 44.2 (17-116) months.
CONCLUSION: DF growth rate was quantitatively assessed. A threshold for volume variation detection was established. DF growth behavior was significantly related to T2 signal. An evidence-based follow-up strategy is proposed. KEY POINTS: • In progressing desmoid fibromatosis, the mean average monthly growth ratio was 10.9 ± 9.2%. • Lesions with muscle/tumor T2 signal ratios lower than 1 tended to be stable or regress over time. • Given the interobserver measurement variability and MRI in-plane spatial resolution, a variation higher than 42.6% in tumor volume is required to confirm punctual progression.

Entities:  

Keywords:  Aggressive fibromatosis; Evidence-based practice; Follow-up studies; Interobserver variability; Magnetic resonance imaging

Mesh:

Year:  2019        PMID: 31468156     DOI: 10.1007/s00330-019-06404-4

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  23 in total

1.  Three-dimensional Radiologic Assessment of Chemotherapy Response in Ewing Sarcoma Can Be Used to Predict Clinical Outcome.

Authors:  Maryam Aghighi; Justin Boe; Jarrett Rosenberg; Rie Von Eyben; Rakhee S Gawande; Philippe Petit; Tarsheen K Sethi; Jeremy Sharib; Neyssa M Marina; Steven G DuBois; Heike E Daldrup-Link
Journal:  Radiology       Date:  2016-03-16       Impact factor: 11.105

2.  Clinical outcomes of systemic therapy for patients with deep fibromatosis (desmoid tumor).

Authors:  Veridiana Pires de Camargo; Mary L Keohan; David R D'Adamo; Cristina R Antonescu; Murray F Brennan; Samuel Singer; Linda S Ahn; Robert G Maki
Journal:  Cancer       Date:  2010-05-01       Impact factor: 6.860

3.  Hyperthermic isolated limb perfusion in locally advanced soft tissue sarcoma and progressive desmoid-type fibromatosis with TNF 1 mg and melphalan (T1-M HILP) is safe and efficient.

Authors:  Sylvie Bonvalot; Françoise Rimareix; Sylvain Causeret; Cécile Le Péchoux; Bérénice Boulet; Philippe Terrier; Axel Le Cesne; Jane Muret
Journal:  Ann Surg Oncol       Date:  2009-10-15       Impact factor: 5.344

4.  Early experience with percutaneous cryoablation of extra-abdominal desmoid tumors.

Authors:  Jennifer L Kujak; Patrick T Liu; Geoffrey B Johnson; Matthew R Callstrom
Journal:  Skeletal Radiol       Date:  2009-09-21       Impact factor: 2.199

5.  RECIST 1.1-Update and clarification: From the RECIST committee.

Authors:  Lawrence H Schwartz; Saskia Litière; Elisabeth de Vries; Robert Ford; Stephen Gwyther; Sumithra Mandrekar; Lalitha Shankar; Jan Bogaerts; Alice Chen; Janet Dancey; Wendy Hayes; F Stephen Hodi; Otto S Hoekstra; Erich P Huang; Nancy Lin; Yan Liu; Patrick Therasse; Jedd D Wolchok; Lesley Seymour
Journal:  Eur J Cancer       Date:  2016-05-14       Impact factor: 9.162

6.  Intraobserver and interobserver variability in computed tomography size and attenuation measurements in patients with renal cell carcinoma receiving antiangiogenic therapy: implications for alternative response criteria.

Authors:  Katherine M Krajewski; Mizuki Nishino; Yoko Franchetti; Nikhil H Ramaiya; Annick D Van den Abbeele; Toni K Choueiri
Journal:  Cancer       Date:  2013-11-21       Impact factor: 6.860

7.  Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis.

Authors:  John J Bissler; Francis X McCormack; Lisa R Young; Jean M Elwing; Gail Chuck; Jennifer M Leonard; Vincent J Schmithorst; Tal Laor; Alan S Brody; Judy Bean; Shelia Salisbury; David N Franz
Journal:  N Engl J Med       Date:  2008-01-10       Impact factor: 91.245

8.  Brain tumor segmentation with Deep Neural Networks.

Authors:  Mohammad Havaei; Axel Davy; David Warde-Farley; Antoine Biard; Aaron Courville; Yoshua Bengio; Chris Pal; Pierre-Marc Jodoin; Hugo Larochelle
Journal:  Med Image Anal       Date:  2016-05-19       Impact factor: 8.545

9.  Association of MRI T2 Signal Intensity With Desmoid Tumor Progression During Active Observation: A Retrospective Cohort Study.

Authors:  Michael R Cassidy; Robert A Lefkowitz; Niamh Long; Li-Xuan Qin; Amanda Kirane; Eman Sbaity; Meera Hameed; Daniel G Coit; Murray F Brennan; Samuel Singer; Aimeé M Crago
Journal:  Ann Surg       Date:  2020-04       Impact factor: 13.787

Review 10.  UK guidelines for the management of soft tissue sarcomas.

Authors:  Adam Dangoor; Beatrice Seddon; Craig Gerrand; Robert Grimer; Jeremy Whelan; Ian Judson
Journal:  Clin Sarcoma Res       Date:  2016-11-15
View more
  2 in total

1.  Efficacy and safety of apatinib for patients with advanced extremity desmoid fibromatosis: a retrospective study.

Authors:  Chuanxi Zheng; Jianguo Fang; Yitian Wang; Yong Zhou; Chongqi Tu; Li Min
Journal:  J Cancer Res Clin Oncol       Date:  2021-01-15       Impact factor: 4.553

2.  The Activity and Safety of Anlotinib for Patients with Extremity Desmoid Fibromatosis: A Retrospective Study in a Single Institution.

Authors:  Chuanxi Zheng; Yong Zhou; Yitian Wang; Yi Luo; Chongqi Tu; Li Min
Journal:  Drug Des Devel Ther       Date:  2020-09-25       Impact factor: 4.162

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.